Clinical TrialAug 6, 2026, 08:04 AM
MIRA Reports Positive Toxicokinetic Findings for Obesity Drug SKNY-1
AI Summary
MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. SKNY-1 is an investigational oral drug candidate for obesity designed to preserve lean body mass. The study showed rapid oral absorption, dose-dependent systemic exposure, and systemic accumulation, which de-risks dose selection. These findings support the advancement of SKNY-1 toward GLP toxicology studies required for IND-enabling development.
Key Highlights
- MIRA Pharmaceuticals reported positive toxicokinetic findings for SKNY-1.
- SKNY-1 is an investigational oral drug candidate for obesity, aiming to preserve lean body mass.
- A 7-day repeated-dose study in Beagle dogs showed rapid oral absorption and dose-dependent systemic exposure.
- Plasma concentrations of SKNY-1 were comparable between male and female animals.
- The data supports dose selection for the planned GLP toxicology program.
- Findings de-risk dose selection and support advancement toward IND-enabling development.
Price Impact
More from MIRA